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Splicing mutations are common causes of β-thalassemia. Some splicing mutations permit normal splicing as well as aberrant splicing, which can give a reduced level of normal β-globin synthesis causing mild disease (thalassemia intermedia). For other mutations, normal splicing is reduced to low levels, and patients are transfusion dependent when homozygous for the disease. Development of therapies for β-thalassemia will require suitable mouse models for preclinical studies. In this study, we report the generation of a humanized mouse model carrying the common IVSI-110 splicing mutation on a BAC including the human β-globin ( Thalassemia is one of the common inherited genetic disorders affecting hemoglobin synthesis. Approximately 300,000 patients with clinically relevant hemoglobinopathies are born each year (1) . In the case of β-thalassemia, which is characterized by a reduction or absence of β-globin chain synthesis resulting in free or unpaired α-globin chains, which aggregate and precipitate within red cells, causing ineffective erythropoiesis and severe anemia.
Over two hundred different mutations have been found that cause β-thalassemia, with splicing mutations among the most common. Most of these mutations activate aberrant cryptic 5' donor or 3' acceptor splice sites without completely abolishing normal splicing. These mutations lead to the production of variable amounts of normal transcripts. Some mutations allow a significant level of normal splicing (such as IVSI-6), leading to thalassemia intermedia, while others reduce normal splicing to low levels (such as IVSI-110) or very low levels (such as IVSI-5 and IVSII-654), causing transfusion-dependent disease in homozygotes.
Because of the complex pathophysiology associated with the hemoglobinopathies, transgenic mouse models are an essential platform for delineating the pathological mechanisms, and, as in vivo model systems, for validating future therapeutic strategies. The humanized mouse model approach, where the transgenic mouse model contains large human genomic fragment(s), has provided valuable insight into the regulatory elements required for the developmental expression of human globin genes (2) (3) (4) (5) (6) . To date, the YAC transgenic mouse for sickle cell anemia, exclusively expressing human β s -globin, is the only mouse thalassemic model expressing a disease gene from the intact hu β-globin locus (7) . Other transgenic mice exclusively expressing human HbA, HbC, HbF and HbS have also been reported, but these mouse models were created by co-injecting large genomic DNA fragments encompassing truncated or hybrid versions of the β-globin locus containing the α1-globin gene (8) (9) (10) . The only β-thalassemia splicing mouse model reported to date is a knock-in model that contains the common IVSII-654 β-thalassemia splicing mutation in the context of the mouse β-globin ( mu β-globin) locus (11) .
With the recent development of targeted modification techniques for BACs such as recE/recT-based homologous recombination (12) (13) (14) (15) , and the availability of site-specific BAC mutagenesis (16) (17) (18) (19) , the main obstacle to generating transgenic mouse models for disease-causing mutations has been overcome. We have recently reported the first humanized mouse model for a deletion mutation, causing β-thalassemia, at codons 41-42 (20 We describe the development and characterisation of a humanized mouse model carrying the IVSI-110 splicing mutation in the context of the genomic hu β-globin locus. This mutation was first described in 1981 and is one of the most common splicing mutations found in the Eastern Mediterranean region (21) . Our results indicate that this humanized IVSI-110 mouse model recapitulates the splicing defect that is typical for IVSI-110 in β-thalassemia patients. This mouse will serve as a platform for testing novel strategies for the restoration of normal splicing.
MATERIAL AND METHODS
Characterisation of the 183 kb genomic fragment containing the hu β-globin locus -The PAC clone 148O22 containing the hu β-globin locus in a 183 kb genomic fragment was first isolated from the RPCI I PAC library (22) (http://www.chori.org/bacpac/) and shown to contain the β-globin locus (23) . The 183 kb genomic fragment was retrofitted into the pEBAC140 cloning vector as a single Not I fragment to generate pEBAC/148β (Fig. 1A ) (24) . Sequencing of the 5' and 3' ends of the genomic insert (data not shown) and alignment with the human genome sequence (GenBank Accession number NT_028310.10) revealed that the genomic insert is 183,039 bp long, with 122,076 bp upstream of the start codon of the ε-globin gene and 17,672 bp downstream of the stop codon of the β-globin gene. Introduction of the IVSI-110 mutation into hu β-globin locus -Using GET recombination, an inducible homologous recombination system for Escherichia coli, the IVSI-110 mutation was introduced into the intact hu β-globin locus contained in a BAC vector (14) . The β-globin locus containing the IVSI-110 mutation was purified from DH10B cells using the Qiagen BAC purification procedure (Qiagen, Hilden, Germany). The 183 kb genomic insert was prepared for microinjection as previously reported (25) . Genotyping of transgenic mice -Genotyping was performed as previously described (25) . In brief, transgenic founder mice and F1 progeny were screened by PCR using the following primer pair: CAGAGGATAGGTCTCCAAAGCTA-3'. The conditions used for the multiplex PCR were: denaturation at 94ºC for 30 sec, annealing at 55ºC for 30 sec and extension at 72ºC for 2 min. After 30 cycles, the PCR products were resolved by 1.5% agarose gel-electrophoresis. Determination of transgene integrity -The longrange integrity of the hu β-globin locus in transgenic lines was examined by Southern blot analysis after digestion of genomic DNA with the Cfr9 I and Sfi I restriction endonucleases (Fermentas, Hanover, MD, USA). Cfr9 I digestion of the hu β-globin locus yields a single 36 kb fragment that contains the γ-, δ-and β-globin genes, while Sfi I digestion cuts the genomic fragment twice in the middle of the fragment. (Fig. 1) (25) . In brief, PCR was performed using the primer pair HM-F 5'-GATGAAGTTGGTGGTGAGGCCCT-3' /HM-R 5'-CCTGAAGTTCTCAGGATCCA-3' on mouse tail genomic DNA. These primers amplify the hu β-globin and mu β-globin sequences equally, yielding 381 bp and 367 bp products respectively. The human and mouse products can be readily distinguished since the murine product contains a unique Nco I site that yields two fragments, 242 bp and 125 bp. The Nco I digested PCR products were run on a 2.0 % 3:1 Nusieve gel (BMA, Rockland, USA). The gel was washed for 45 min, in 7% trichloroacetic acid and vacuum-dried at 65 ο C onto blotting paper. The dried radioactive gel was exposed to a Low Energy Storage Phosphor Screen (Molecular Dynamics, Amersham Pharmacia Biotech, Buckinghamshire, UK) and the Phosphor Screen was scanned using the Storm 840 Scanner (Molecular Dynamics). Each band corresponding to mu β-globin and hu β-globin PCR product was quantitated using Image Quant (Molecular Dynamics). Location of transgene integration siteFluorescence in situ hybridisation (FISH) analysis was used to examine transgene integration sites and confirm hemizygosity or homozygosity for the transgene in mice exclusively expressing hu β-globin. Fibroblasts isolated from tail biopsies, were grown in Dulbecco's modified Eagles medium (Sigma, St Louis, MO) supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin and 100 µg/ml streptomycin. The fibroblasts were harvested after exposure to colcemid for 2 hours. Chromosome preparations were obtained using standard techniques and hybridized with a pEBAC/148β DNA probe. The probe was labelled with digoxigenin, (Roche) and detected with rhodamine conjugated anti-digoxigenin, to locate the inserted transgenes. The slides were mounted in Vectashield (Vector Laboratories) containing DAPI counterstain. The cells were examined and analysed using a Zeiss epifluorescence microscope with appropriate filters and images were captured using Cytovision imaging equipment and software (Applied Imaging Corp., Santa Clara, CA). Metaphases and interphase nuclei were analysed for localized signals and chromosome identification achieved by analysis of the reversed DAPI banding pattern.
RT-PCR analysis -Total RNA was prepared using the Tri-Reagent BD system (Molecular Research Center, Cincinnati, USA) as described by the manufacturer. cDNA was synthesized using random hexamers as primers. Primers used to amplify the sequence between exon 1 and exon 2 were: forward primer 5'-CGCCTCGAGGAGAAGTCTCCGTTAC-3' and reverse primer 5'-CGCGAATTCCCCATAACAGCACAGGAGT -3'. The PCR was performed using the following conditions: denaturation at 94ºC for 0:30 min, annealing at 55ºC for 30 sec and extension at 72ºC for 30 sec. After 30 cycles, the PCR products resolved on a 2% Nusieve GTG agarose gel. The above primers amplified a 170 bp and a 189 bp product from the hu β-globin gene, which corresponds to the normal and aberrantly spliced mRNA respectively.
Sequencing of RT-PCR products -
The PCR amplified products were digested with Xho I and EcoR I and cloned into the respective sites of pBluescript-KS+. Colonies were picked based on blue/white color selection and verified by sequencing using Big Dye Terminator Kit V3.1 (Perkin-Elmer, USA) according to manufacturer's specifications, and using the RT-PCR forward primer as above. In brief sequencing PCR was performed using the following conditions: rapid thermal ramp to 96 o C, hold at 96 o C for 30 sec, rapid thermal ramp to 50 o C, hold at 50 o C for 15 sec, rapid thermal ramp to 60 o C, hold at 60 o C for 4 min. After 25 cycles, rapid thermal ramp to 4 o C. Hematological analysis -Blood was collected from transgenic mice ≥8 weeks of age by retroorbital bleeding. Full blood examination (FBE) was performed on whole blood collected into tubes containing EDTA. FBE was performed using an automated Roche Cobas Helios hematological analyser at the Walter and Eliza Hall Institute, Melbourne, Australia. A minimum of two weeks was allowed between repeat samples, when such samples were necessary, to minimize the distortion of hematological parameters by frequent bleeding. Cellulose acetate gel electrophoresis was used to visualize hemoglobin tetramers. Samples containing approximately equal amounts of hemoglobin were run on cellulose acetate membranes (Helena Laboratories). Hemoglobin bands were visualized using Ponceau S stain. Measurement of globin chain synthesis -The measurement of mu β-globin and hu β-globin chain synthesis was performed by highpressure liquid chromatography (HPLC) as previously described (25) . Red blood cells (20 µl) were lysed in 500 µl of lysis buffer (0.1 M 2-mercaptoethanol, 0.1M HCl), and then made up to 1 ml with 500 µl of 50 % aqueous acetonitrile. The lysate was centrifuged and the supernatant was analysed by HPLC. Globin chain separation was performed by loading 30 µl of lysed red cells onto a Vydac C4 column (Vydac, Hesperia, USA). The proteins eluting from the column were measured at 220 nm, 280 nm and 413 nm with an Agilent 1100 Diode Array Detector. Peak protein fractions were collected and analysed by tandem mass spectrometry in order to confirm globin chain type.
RESULTS
Creation and characterisation of BAC transgenic mice -In this study, our aim was to establish a humanized mouse model carrying the IVSI-110 splicing mutation and determine whether the hu β-globin pre-mRNA produced in mice was aberrantly spliced as in humans. Founder mice were carrying either the normal or IVSI-110 genomic fragment were identified by screening genomic DNA by Metaphase spreads of fibroblast cells were prepared from F0 progeny. The transgenic founders were all found to contain a single integration site ( Fig. 2A) . The integrated BAC DNA was located using labelled insert DNA and chromosome identification made on the basis of the banding pattern obtained from the inverted DAPI metaphase image. In the founder containing the normal hu β-globin locus, the transgene was proximally located on chromosome 14, while in the founder containing the IVSI-110 locus the transgene was medially located on chromosome 1 ( Fig. 2A) .
Genotype determination -To determine the degree of hematological complementation of the hu β-globin locus in a thalassemic environment, transgenic mice were bred onto a mu β th-3/+ and a mu β th-3/th-3 background. The transgenic mice were genotyped by multiplex PCR using genomic DNA. Three genes were amplified by PCR (Fig.  2B) . The bottom band represents the We have previously reported that homozygosity for two copies of the normal locus was necessary to rescue the embryonic lethal mu β th-3/th-3 mice, with the mice displaying normal hematological parameters as measured by FBE. We were unable to identify any IVSI-110 transgenic on a mu β th-3/th-3 background at birth indicating that the level of globin expression is insufficient to support fetal growth to birth. This is due to the low level of hu β-globin expression caused by the IVSI-110 mutation. Transgene copy number determination -Two transgenic lines were analysed by quantitative radioactive PCR. Since the human and the mouse globin genes are very similar at the DNA sequence, the primers were designed to amplify both the hu β-globin and mu β-globin genes. However, only the amplified mouse PCR product contains an internal Nco I restriction site, which was used to differentiate between the mouse and human-specific β-globin PCR product. The PCR products generated using the HM primers set were digested with Nco I and separated by agarose gel electrophoresis (Fig. 2C) . The two lower bands represent the two mouse-specific products, 125 and 242 bp while the top band represents the undigested hu β-globin gene, 381 bp. As expected, the wild type Nco I digested mouse control PCR produced two mousespecific PCR products, while the human control PCR reaction produced one human-specific PCR product. The relative intensity of hu β-globin-specific PCR product was compared to the mu β-globin-specific PCR products on a wild type background (which contains four adult β-globin genes) and on a mu β th-3/+ (which contains two adult β-globin genes). Using this approach, the transgene copy number was determined. Both transgenic lines contained two copies of the hu β-globin locus (Fig. 2C) . (Fig. 3A) (Fig. 3) . This is thought to be due to post translational events, where reduced synthesis of globin pre-mRNA in the humanized IVSI-110 mouse model was examined. RT-PCR was performed on RNA derived from whole blood, BM and spleen from the humanized IVSI-110 mouse model and compared with RNA derived from blood isolated from a homozygous IVSI-110 β-thalassemia patients (Fig. 4) . PCR primers specific for the hu β-globin gene were used to amplify the correctly spliced hu β-globin mRNA spaning the 3' end of exon 1 to the 5' end of exon 2 regions. As a control we used transgenic mouse containing the normal hu β-globin (Fig. 4) .
As determined by RT-PCR transgenic mice that containing the IVSI-110 β-globin locus displayed one aberrantly spliced product. Detailed sequence analysis of cloned BM RT-PCR products, revealed that the +110 mutation was recognized as the expected 3' splice site. This aberrant splice product was identified in the BM, spleen and blood of mice as well as in the blood of IVSI-110 β-thalassemia patients.
We noted quantitative differences in the amount of aberrant RT-PCR splice products amplified by PCR. In the BM and spleen, +110 splice product was present in greater amounts compared with correctly spliced β-globin mRNA, while in the blood of mice and IVSI-110 β-thalassemia patients the normal splice product was the predominate mRNA species. Presumably the difference in relative mRNA levels is due to mRNA instability.
We compared the strength of the authentic and aberrant splice sites using the Sapiro and Senapathy (S&S) matrix (26) . The +110 3'ss scored 80.1, while the natural 3'ss scored 84.5 (Fig. 4) . While the +110 3'ss scored lower than the natural 3'ss, it is not clear how the spliceosome can selectively discriminate against the authentic 3'ss in preference for the weaker aberrant splice site. There are several studies, which report that RNA sequence elements bound by serine /arginine-rich (SR) family of proteins promotes the use of 5' and 3' splice sites through proteinprotein and protein-RNA interactions. SR proteins can be either splicing activators or repressers, depending on where they bind to the pre-mRNA. Intronic binding of SR proteins has previously been reported to inhibit splicing (27). Since the IVSI-110 mutation promoted intronic aberrant splicing, the exonic splice enhancer algorithm ESEfinder was used to investigate whether the IVSI-110 mutation interfered with four putative SR splicing factors; SR protein SF2/ASF, SC35, SRp40 and SRp55 (28 (Table 1) .
DISCUSSION
Transgenic mice containing large genomic fragments are increasingly being developed, as in vivo model systems to facilitate our understanding of the biology and etiology of human diseases. With most of the human genome available as BAC clones, humanized BAC/YAC transgenic mice are increasingly the in vivo model systems of choice to map regulatory regions and to unravel the molecular mechanisms underlying developmental regulation and expression of functional genomic loci (2-6). With the growing demand for more sophisticated murine models to emulate human disease, BAC transgenics in combination with other gene knockout technologies are seen as important experimental tools for disease modelling.
In this study, we demonstrate that mice transgenic for the human β-globin locus, with the IVSI-110 G to A mutation produce the same aberrant spliced product found in IVSI-110 β-thalassemia patients. We noted quantitative differences in the level of aberrant +110 RT-PCR splice product between bone marrow and peripheral blood. While the bone marrow sample showed more aberrant +110 RT-PCR splice product relative to normal β-globin, the blood samples derived from IVSI-110 transgenic mice and IVSI-110 β-thalassemia patients exhibited the reverse. We attribute the difference in relative ratios of RT-PCR products to mRNA instability. The +110 aberrant splice product generates a premature stop codon, which is known to trigger the nonsensemediated mRNA decay process (NMD). This pathway degrades mRNAs containing premature termination codons generated by point mutations and/or splicing alterations, whose translation product may be detrimental to the cell (29) .
Although large genomic transgenes are likely to contain all the necessary regulatory elements required for tissue-specific and position-independent expression, mouse models using such transgenes do not always mirror the expression of the endogenous gene in humans (25, 30) . The exact reason for this is not clear, but it may reflect the level of transcriptional compatibility between the two species.
We next investigated mu β th-3/+ carrying two copies of the IVSI-110 β-globin locus ( Despite the many mutations causing alternative splicing identified to date, the reasons why mutations vary from mild to severe in their effects are poorly understood. Splicing relies on the correct recognition of ciselements (the 5' and 3' splice sites and the branch point), but these are not sufficient to define exon-intron boundaries. Additional cisacting elements such as exonic or intronic splicing enhancers and silencers significantly influence normal and alternative splice site selection. These elements are recognized by trans-acting factors, including the SR proteins and huRNPs (27). We can only speculate that the IVSI-110 mutation may have disrupted the binding of an intronic silencer, reducing exon definition and allowing the recruitment of the splicing machinery to upstream aberrant 3' splice sites.
Kole and colleagues were the first to attempt therapeutic modulation of alternative splicing by targeting antisense oligonucleotides (AO) to the aberrant splice site to restore splicing specificity. This strategy prevents the selection of the aberrant splice site and thus favouring the recognition of the correct splice site by the splicing machinery. By using in vitro and cellular assays, they demonstrated inhibition of aberrant splicing in two common β-thalassemia mutations, IVSII-654 and IVSII-705 (31, 32) . In the case of the IVSI-110 mutation, efficient inhibition of aberrant splicing was achieved not by targeting the aberrant splice site, but the natural branch point sequence of the first intron (32) . More recently, AO have been shown to correct aberrant splicing in vivo using a transgenic mouse model in which EGFP expression was interrupted by an intron containing IVSII-654 splicing mutation (33) . Systemic delivery of AO restored EGFP expression in all tissues that took up AO, providing evidence that AO can be used in vivo to restore normal splicing. They found correction of aberrant splicing was variable for different tissues, but this may reflect the levels of transgene expression. Although this animal model represents an excellent in vivo model system for the investigation of delivery and activity of various AO chemistries, it is not clinically relevant with respect to anemia and extramedullary erythropoiesis.
An alternative approach to restore splicing specificity, lost through mutations, would be the use of bifunctional AO's. By combining an antisense-targeting domain and peptide-recruiting domain it may be possible to recruit specific splicing factors that might influence splicing in a positive or negative manner. This approach has recently been shown to specifically restore wild type splicing when directed to defective BRACA1 or SMN2 premRNA (34, 35) .
In this study, we show that this humanized IVSI-110 mouse model recapitulates the splicing defect that is typical for β-thalassemia patients carrying the IVSI-110 mutation. We show that the humanized transgenic mu β th-3/+ , carrying the IVSI-110 hu β-globin locus, represents a physiologically relevant in vivo model system, which can provide a unique opportunity for the development and evaluation of various therapeutic strategies such as AO and pharmacological-based therapies. ). The transgene copy number was determined for each transgenic line as indicated. 
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